Trials of Roche's Perjeta show it could help extend the lives of women with advanced breast cancer by over a year compared to existing treatments. The results from the CLEOPATRA study are a ...
The European Union’s Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion to Roche’s Perjeta (pertuzumab) for use in combination with herceptin (trastuzumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback